Boston Scientific Corp.'s stock dips on news that it's holding all shipment of its implantable cardiac defibrillators and cardiac resynchronization therapy devices, after discovering it missed filings with the Food & Drug Administration.
Boston Scientific Corp. (NYSE:BSX) is holding all shipments of its implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators and pulling all inventory from the field after discovering that it missed a pair of filings with the Food & Drug Administration.
The medical device-making giant said it failed to notify the FDA of two changes to its manufacturing process for its Cognis, Confient, Livian, Prizm, Renewal, Teligen and Vitality ICDs and CRT-Ds. The changes were "successfully validated" and there is no risk to patient safety, according to a press release. Boston Scientific's pacemakers and other products are not affected by the move.
Medical device company Bausch + Lomb won FDA approval for its Trulign Toric intraocular lens, the 1st...
California medical device maker Claret Medical's embolic protection technology captures debris...
Texas-based Galt Medical Corp. is reportedly laying off 139 workers as it shutters its hometown plant...
Medtronic's fiscal 4th-quarter and 2013 profits slide on low-single-digit revenue growth, but the...
Wound Management Technologies strikes a deal with the IRS to settle payroll tax liabilities and...